On June 18, CARSGEN Therapeutics, a pioneer in the field of CAR-T cell therapy, officially listed on the Hong Kong, S.A.R., China Stock Exchange, offering 94.747 million shares, priced at HK $32.80 per share, raising a net of about HK $2.94 billion.
A diversified product line
Since establishment, CARSGEN Therapeutics has been focused on the research and development of the innovation of CAR-T cell therapy and differentiated innovative medical supplies products. The CAR-T product candidates of CARSGEN are evidence-based novel tumor-associated antigens that have been carefully designed and optimized to reduce the side effects common to existing CAR-T therapies. CARSGEN Therapeutics has independently developed 11 product candidates for the treatment of solid tumors and hematologic malignancies.
R&D line of CARSGEN Therapeutics (Source: reference 1)